Psoriasis drug Stelara gets expanded U.S. approval for teens

Reuters Health Information: Psoriasis drug Stelara gets expanded U.S. approval for teens

Psoriasis drug Stelara gets expanded U.S. approval for teens

Last Updated: 2017-10-13

By Reuters Staff

(Reuters) - Johnson and Johnson said on Friday it has received an expanded U.S. approval for its psoriasis drug Stelara to treat adolescent patients aged 12 and over with moderate to severe cases of the unsightly skin condition.

Stelara (ustekinumab) was already approved to treat adults with psoriasis. It is also approved to treat adults with the related condition psoriatic arthritis, and for moderate to severe Crohn's disease.

About one-third of people who develop plaque psoriasis do so before 20 years of age, Johnson and Johnson said.

"Psoriasis is a highly visible disease, and it is essential that these younger patients and their caregivers have options that can effectively reduce the difficult-to-conceal and often misunderstood plaques," Michael Siegel of the National Psoriasis Foundation said in a statement.

Stelara is one of J and J's most important pharmaceutical products, with 2017 sales expected to reach $3.7 billion and increasing to more than $5 billion by 2021, according to Thomson Reuters data.

© Copyright 2013-2018 GI Health Foundation. All rights reserved.
This site is maintained as an educational resource for US healthcare providers only. Use of this website is governed by the GIHF terms of use and privacy statement.